ClinicalTrials.gg
CompletedNCT02499120Updated Sep 8, 2023Results posted

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

A Phase 2 interventional study of palbociclib and Cetuximab in Squamous Cell Carcinoma of the Head and Neck (SCCHN), sponsored by Pfizer. Completed at 71 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-08.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies in Squamous Cell Carcinoma of Head and Neck by Pfizer — 3 open to participants now, 5 under way, none of them phase 3. Squamous Cell Carcinoma of Head and Neck · Pfizer.

Enrollment
15th of 30
125 · median 105
Started
2015
with 3 others
Phase 2
6 of 30
none open now
Registered
6th of 30
by date

Among the 30 studies in Squamous Cell Carcinoma of Head and Neck by Pfizer, this one is the 15th largest by enrollment, is one of 4 that started in 2015, is one of 6 in phase 2, and was the 6th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

3 of the 30 studies in Squamous Cell Carcinoma of Head and Neck by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Squamous Cell Carcinoma of Head and Neck by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether the combination of palbociclib with cetuximab is superior to cetuximab in prolonging overall survival in HPV-negative, cetuximab-naive patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

03

Conditions studied

  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Keywords

  • palbociclib, cetuximab, human papillomavirus, squamous cell carcinoma, head and neck cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, not amenable for salvage surgery or radiotherapy.
  • as defined per v. 1.1. Tumor lesions previously irradiated or subjected to other locoregional therapy will only be deemed measureable if disease progression at the treated site after completion of therapy is clearly documented.
  • HPV- negative SCCHN tumor as determined per institutional standard (eg, p16 IHC; multiplex nucleic acid sequence based amplification [NASBA] or other polymerase chain reaction [PCR]-based assays).
  • Documented progressive disease according to RECIST v1.1 (Appendix 2) following receipt of at least 2 cycles of one platinum-containing chemotherapy regimen administered for R/M disease (min. 50 mg/m2 for cisplatin, minimum area under the curve [AUC] > 4 for carboplatin).
  • Availability of a tumor tissue specimen (ie, archived formalin fixed paraffin embedded tissue [block preferred, or 15 unstained slides]), which will be used for centralized, retrospective biomarker analysis. If archived tumor tissue is not available, then a de novo will be required for patient participation.

Key Exclusion Criteria:

  • Prior nasopharyngeal cancer, salivary gland or sinus tumors.
  • More than one chemotherapeutic regimen given for R/M disease. Prior treatment with immunotherapy is allowed.
  • Known active uncontrolled or symptomatic central nervous system (CNS) , carcinomatous meningitis, or as indicated by clinical symptoms, cerebral edema, and/or progressive growth. Patients with a history of or cord compression are eligible if they have been definitively treated with local therapy (eg, radiotherapy, stereotactic surgery) and are clinically stable off anticonvulsants and for at least 4 weeks before randomization.
  • Progressive disease within 3 months after completion of curatively intended treatment for locoregionally advanced SCCHN.
  • Difficulty swallowing capsules.
  • Prior use of cetuximab in the R/M disease treatment setting (except cetuximab during curative radiotherapy)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Palbociclib plus Cetuximab

    Palbociclib, 125 mg, orally once daily (QD) with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.

    Drug: palbociclib · Drug: Cetuximab

  • Active comparator
    Placebo plus Cetuximab

    Placebo orally QD with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.

    Drug: Cetuximab · Drug: Placebo

Interventions

  • Palbociclib will be supplied as capsules containing 75 mg, 100 mg, or 125 mg equivalents of palbociclib free base. Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.

    Also known as: IBRANCE, PD-0332991

  • Cetuximab injection for IV infusion will be provided in 100 mg/50 mL, single-use vials, and 200 mg/100 mL, single-use vials. In Japan, cetuximab will be provided in 100 mg/20 mL, single-use vials. Administered, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.

    Also known as: ERBITUX

  • DrugPlacebo

    Placebo for palbociclib will be indistinguishable from the palbociclib capsules and will be supplied as capsules matching in size and color the various palbociclib formulations. Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization to the date of death due to any cause. OS (in months) was calculated as (date of death - randomization date +1)/30.4. For participants lacking survival data beyond the date of their last follow-up, the OS time was censored on the last date they were known to be alive. Participants lacking survival data beyond randomization had their OS times be censored at randomization. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.

    Time frame: Baseline up to primary completion date (PCD) (about 34 months)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from the date of randomization to the date of the first documentation of objective progression of disease (PD) or death due to any cause, whichever was earlier. Estimates of the PFS curves from the Kaplan Meier method were presented.

    Time frame: Baseline up to PCD (about 34 months)

  2. Percentage of Participants With Objective Response (OR)

    OR was defined as the overall complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Objective response rate was defined as the proportion of participants with best overall response (BOR) of CR or PR relative to all randomized.

    Time frame: Baseline up to PCD (about 34 months)

  3. Percentage of Participants With Clinical Benefit Response (CBR)

    CBR was defined as the overall CR, PR, or stable disease\>=24 weeks according to the RECIST version 1.1. Clinical benefit response rate was defined as the proportion of participants with CR, PR, or stable disease\>= 24 weeks relative to all randomized participants and randomized participants with measurable disease at baseline.

    Time frame: Baseline up to PCD (about 34 months)

  4. Duration of Response (DR)

    DR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used. DR was calculated as \[the date response ended (ie, date of PD or death) - first CR or PR date + 1\]/30.4.

    Time frame: Baseline up to PCD (about 34 months)

  5. Number of Participants With Treatment-Emergent Adverse Events(TEAEs)

    AE was defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of the causal relationship to study treatment. TEAEs were defined as AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Causality to study treatment was determined by the investigator. Severity was graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

    Time frame: From the first dose through and including 28 calendar days after the last administration of the study treatment (up to 6.9 years)

  6. Number of Participants With Laboratory Abnormalities

    The hematology, chemistry and coagulation tests were included in the laboratory examination. Hematology evaluation included hemoglobin, platelets, white blood cell, absolute neutrophils, absolute lymphocytes. Chemistry evaluation included alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, blood urea nitrogen (BUN) or urea, creatinine, uric acid, glucose (non-fasted), albumin, phosphorus or phosphate and hemoglobin A1c (HbA1c). Coagulation evaluation included activated partial thromboplastin time/partial thromboplastin time, international normalized ratio (INR) or prothrombin time.

    Time frame: From the Screening (Day -28) through and including 28 calendar days after the last administration of the study treatment (up to 7 years)

  7. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)

    The EORTC QLQ-C30 is a 30 item questionnaire composed of 5 multi-item functional subscales (physical, role, cognitive, emotional, and social functioning), 3 multi-item symptom scales (fatigue, nausea/vomiting, and pain), a global health/quality of life (QOL) subscale, and 6 single items assessing other cancer related symptoms (dyspnea, sleep disturbance, appetite, diarrhea, constipation, and the financial impact of cancer). The questionnaire employed twenty-eight 4 point Likert scales with responses from "not at all" to "very much" and two 7 point Likert scales for global health and overall QOL. For functional and global QOL scales, higher scores represented a better level of functioning and all scores were converted to a 0 to 100 scale. For symptom oriented scales, a higher score represented more severe symptoms, and all scores were converted to a 0-100 scale. Negative changes from baseline indicate deterioration in functioning / global QoL scales and improvement in symptom scales.

    Time frame: Baseline up to PCD (about 34 months)

  8. Change From Baseline in European Organization for Research and Treatment of Cancer Head and Neck Module35 (EORTC QLQ-H&N35)

    The EORTC QLQ-H\&N35 is designed to be used together with the core QLQ-C30. The recall period for the items in the module was "the past week". Items hn1 to hn30 were scored on 4 point Likert type categorical scales ("not at all", "a little", "quite a bit", "very much"). Items hn31 to hn35 had a "no/yes" response format. The scores were transformed into 0 to 100 scales, with a high score implying a high level of symptoms.Negative changes from baseline indicate deterioration in functioning / global QoL scales and improvement in symptom scales.

    Time frame: Baseline up to PCD (about 34 months)

  9. Summary of PFS and OS for P16 Negative (%Positive Tumor Cells < 70%)

    A central test was defined as the tumor tissue-based p16 IHC test performed at a central laboratory (Ventana). The analysis of concordance between HPV status as assessed by local or central laboratory included the number and percentage of participants with p16 detected or not detected at the central laboratory, given that all local testing must have been negative for HPV in order for the patient to be eligible for the study. Initial analysis of the p16 status was based on the conventional cutoff of 70% p16-positive tumor cells to call out cases that might be considered HPV-positive. P16 expression was scored as positive if strong and diffuse nuclear and cytoplasmic staining was present in at least 70% of the tumor cells.

    Time frame: Screening

  10. Summary of PFS and OS Based on Investigator Assessment by Rb Expression >= 1%

    Rb expression in the palbociclib and cetuximab treatment group, the relationship of the biomarker (individually) with PFS and OS were explored using graphical methods such as box plots, at baseline. The tumors of participants were Rb-positive, which was defined by Rb IHC with\>=1% positive tumor cells.

    Time frame: Screening

  11. Trough Plasma Concentration (Ctrough) and Within-participant Mean Steady-state Pre-dose Concentration (WPM-Ctrough) at Steady State for Palbociblib

    Ctrough is steady-state pre-dose concentration, which was observed directly from data. WPM-Ctrough is within-participant mean steady-state pre-dose concentration. For palbociclib, a steady-state trough was to be defined as a pre-dose plasma concentration following at least 7 consecutive days of 125 mg daily dose without dosing interruption and the time window for the PK collection was to be between 24 hr +/- 2 hr and 24 min post-dose the day prior to PK collection and no more than 1 hr post-dose on the day of PK collection.

    Time frame: Pre-dose of Day 15 in Cycle 1 and Cycle 2

  12. Ctrough and Cendinf, WPM-Ctrough and WPM-Cendinf at Steady State for Serum Cetuximab

    Ctrough is steady-state pre-dose concentration. Cendinf is steady-state end-of-infusion concentration. Ctrough and Cendinf were observed directly from data. WPM-Ctrough and WPM-Cendinf are within-participant mean steady-state pre-dose concentration and end-of-infusion concentration. Acceptance criteria for a steady-state Cendinf was defined as a PK sample that was 1) collected after at least 3 consecutive weeks of cetuximab IV infusions without interruption or prior dose reduction and 2) was collected at the end of cetuximab infusion time +/- 10% of the actual duration of the cetuximab infusion.

    Time frame: Pre-dose and end-of infusion of Day 15 in Cycle 1 and Cycle 2

07

Results

Posted Sep 20, 2019

Participant flow

Participant flow — Overall Study
MilestonePalbociclib + CetuximabPlacebo + Cetuximab
Started6560
Received treatment6460
Completed00
Not completed6560
Withdrew: Death5243
Withdrew: Lost to follow-up12
Withdrew: Participant refused further follow-up10
Withdrew: Withdrawal by subject25
Withdrew: Other910

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time from the date of randomization to the date of death due to any cause. OS (in months) was calculated as (date of death - randomization date +1)/30.4. For participants lacking survival data beyond the date of their last follow-up, the OS time was censored on the last date they were known to be alive. Participants lacking survival data beyond randomization had their OS times be censored at randomization. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.

Time frame:
Baseline up to primary completion date (PCD) (about 34 months)
Reported as:
Median · months
Overall Survival (OS)
monthsPalbociclib + CetuximabPlacebo + Cetuximab
Overall Survival (OS)9.7 (7.3 to 13.9)7.8 (6.7 to 10.6)
Statistical analysis
  • Palbociclib + Cetuximab vs Placebo + Cetuximab · Log Rank · p = 0.1800 (1-sided p-value was from the log-rank test stratified by stratification factors ECOG(Eastern Cooperative Oncology Group) per randomization.) · Hazard ratio (hr): 0.820 · 95% CI 0.536 to 1.253
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from the date of randomization to the date of the first documentation of objective progression of disease (PD) or death due to any cause, whichever was earlier. Estimates of the PFS curves from the Kaplan Meier method were presented.

Time frame:
Baseline up to PCD (about 34 months)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsPalbociclib + CetuximabPlacebo + Cetuximab
Progression Free Survival (PFS)3.9 (3.6 to 5.6)4.6 (2.3 to 5.5)
Statistical analysis
  • Palbociclib + Cetuximab vs Placebo + Cetuximab · Log Rank · p = 0.4953 (1-sided p-value was from the log-rank test stratified by stratification factors ECOG per randomization.) · Hazard ratio (hr): 1.000 · 95% CI 0.669 to 1.495
SecondaryPercentage of Participants With Objective Response (OR)

OR was defined as the overall complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Objective response rate was defined as the proportion of participants with best overall response (BOR) of CR or PR relative to all randomized.

Time frame:
Baseline up to PCD (about 34 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response (OR)
Percentage of participantsPalbociclib + CetuximabPlacebo + Cetuximab
Percentage of Participants With Objective Response (OR)27.7 (17.3 to 40.2)25.0 (14.7 to 37.9)
SecondaryPercentage of Participants With Clinical Benefit Response (CBR)

CBR was defined as the overall CR, PR, or stable disease\>=24 weeks according to the RECIST version 1.1. Clinical benefit response rate was defined as the proportion of participants with CR, PR, or stable disease\>= 24 weeks relative to all randomized participants and randomized participants with measurable disease at baseline.

Time frame:
Baseline up to PCD (about 34 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Benefit Response (CBR)
Percentage of participantsPalbociclib + CetuximabPlacebo + Cetuximab
Percentage of Participants With Clinical Benefit Response (CBR)36.9 (25.3 to 49.8)36.7 (24.6 to 50.1)
SecondaryDuration of Response (DR)

DR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used. DR was calculated as \[the date response ended (ie, date of PD or death) - first CR or PR date + 1\]/30.4.

Time frame:
Baseline up to PCD (about 34 months)
Reported as:
Median · months
Duration of Response (DR)
monthsPalbociclib + CetuximabPlacebo + Cetuximab
Duration of Response (DR)7.6 (3.7 to 7.7)7.4 (3.6 to NA)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events(TEAEs)

AE was defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of the causal relationship to study treatment. TEAEs were defined as AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Causality to study treatment was determined by the investigator. Severity was graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Time frame:
From the first dose through and including 28 calendar days after the last administration of the study treatment (up to 6.9 years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events(TEAEs)
ParticipantsPalbociclib + CetuximabPlacebo + Cetuximab
AEs (all causality)6156
AEs (treatment-related)5848
SAEs (all causality)2519
SAEs (treatment-related)72
Grade 3 or 4 AEs (all causality)3319
Grade 5 AEs (all causality)1511
Grade 3 or 4 AEs (treatment-related)3410
Grade 5 AEs (treatment-related)10
SecondaryNumber of Participants With Laboratory Abnormalities

The hematology, chemistry and coagulation tests were included in the laboratory examination. Hematology evaluation included hemoglobin, platelets, white blood cell, absolute neutrophils, absolute lymphocytes. Chemistry evaluation included alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, blood urea nitrogen (BUN) or urea, creatinine, uric acid, glucose (non-fasted), albumin, phosphorus or phosphate and hemoglobin A1c (HbA1c). Coagulation evaluation included activated partial thromboplastin time/partial thromboplastin time, international normalized ratio (INR) or prothrombin time.

Time frame:
From the Screening (Day -28) through and including 28 calendar days after the last administration of the study treatment (up to 7 years)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsPalbociclib + CetuximabPlacebo + Cetuximab
Number of Participants With Laboratory Abnormalities6155
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)

The EORTC QLQ-C30 is a 30 item questionnaire composed of 5 multi-item functional subscales (physical, role, cognitive, emotional, and social functioning), 3 multi-item symptom scales (fatigue, nausea/vomiting, and pain), a global health/quality of life (QOL) subscale, and 6 single items assessing other cancer related symptoms (dyspnea, sleep disturbance, appetite, diarrhea, constipation, and the financial impact of cancer). The questionnaire employed twenty-eight 4 point Likert scales with responses from "not at all" to "very much" and two 7 point Likert scales for global health and overall QOL. For functional and global QOL scales, higher scores represented a better level of functioning and all scores were converted to a 0 to 100 scale. For symptom oriented scales, a higher score represented more severe symptoms, and all scores were converted to a 0-100 scale. Negative changes from baseline indicate deterioration in functioning / global QoL scales and improvement in symptom scales.

Time frame:
Baseline up to PCD (about 34 months)
Reported as:
Mean · units on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)
units on a scalePalbociclib + CetuximabPlacebo + Cetuximab
Global health status / QOL2.82 (-1.49 to 7.13)2.69 (-1.70 to 7.08)
Functional scale: Physical functioning0.74 (-3.26 to 4.73)-0.46 (-4.59 to 3.66)
Functional scale: Role functioning-0.41 (-5.91 to 5.09)-1.60 (-7.28 to 4.08)
Functional scale: Emotional functioning4.16 (0.13 to 8.18)3.56 (-0.57 to 7.69)
Functional scale: Cognitive functioning-1.47 (-5.14 to 2.21)-1.23 (-5.06 to 2.59)
Functional scale: Social functioning1.24 (-4.43 to 6.90)2.08 (-3.76 to 7.92)
Symptom scale/item: Fatigue-2.79 (-7.04 to 1.46)-5.12 (-9.50 to -0.75)
Symptom scale/item: Nausea and vomiting-0.87 (-2.63 to 0.90)-1.04 (-2.82 to 0.74)
Symptom scale/item: Pain-5.98 (-11.06 to -0.90)-6.10 (-11.32 to -0.87)
Symptom scale/item: Dyspnoea3.07 (-2.15 to 8.30)5.09 (-0.27 to 10.45)
Symptom scale/item: Insomnia-4.62 (-10.33 to 1.08)-5.02 (-10.88 to 0.84)
Symptom scale/item: Appetite loss2.25 (-3.89 to 8.38)-0.69 (-7.04 to 5.67)
Symptom scale/item: Constipation-4.12 (-10.30 to 2.06)-1.33 (-7.72 to 5.07)
Symptom scale/item: Diarrhoea4.26 (1.34 to 7.17)1.74 (-1.24 to 4.73)
Symptom scale/item: Financial difficulties-5.26 (-11.61 to 1.10)-0.27 (-6.83 to 6.29)
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Head and Neck Module35 (EORTC QLQ-H&N35)

The EORTC QLQ-H\&N35 is designed to be used together with the core QLQ-C30. The recall period for the items in the module was "the past week". Items hn1 to hn30 were scored on 4 point Likert type categorical scales ("not at all", "a little", "quite a bit", "very much"). Items hn31 to hn35 had a "no/yes" response format. The scores were transformed into 0 to 100 scales, with a high score implying a high level of symptoms.Negative changes from baseline indicate deterioration in functioning / global QoL scales and improvement in symptom scales.

Time frame:
Baseline up to PCD (about 34 months)
Reported as:
Mean · units on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Head and Neck Module35 (EORTC QLQ-H&N35)
units on a scalePalbociclib + CetuximabPlacebo + Cetuximab
Symptom scale/item: Pain-3.57 (-8.56 to 1.43)-0.41 (-5.54 to 4.73)
Symptom scale/item: Swallowing-4.34 (-8.79 to 0.10)-1.47 (-6.03 to 3.09)
Symptom scale/item: Senses problems-1.58 (-7.22 to 4.05)-1.88 (-7.72 to 3.96)
Symptom scale/item: Speech problems-4.54 (-9.21 to 0.13)-2.69 (-7.51 to 2.13)
Symptom scale/item: Trouble with social eating-5.55 (-10.14 to -0.96)-0.71 (-5.42 to 4.01)
Symptom scale/item: Trouble with social contact-1.27 (-5.68 to 3.15)3.45 (-1.14 to 8.04)
Symptom scale/item: Less sexuality-3.32 (-11.44 to 4.80)4.90 (-3.72 to 13.53)
Symptom scale/item: Teeth-1.59 (-8.91 to 5.74)-1.88 (-9.29 to 5.53)
Symptom scale/item: Opening mouth0.35 (-5.29 to 5.99)0.22 (-5.56 to 5.99)
Symptom scale/item: Dry mouth-6.30 (-10.50 to -2.10)3.44 (-0.82 to 7.71)
Symptom scale/item: Sticky saliva-3.91 (-9.70 to 1.88)4.68 (-1.22 to 10.58)
Symptom scale/item: Coughing-3.99 (-8.67 to 0.69)-1.72 (-6.48 to 3.04)
Symptom scale/item: Felt ill1.320 (-4.22 to 6.86)0.12 (-5.45 to 5.70)
Symptom scale/item: Pain killers-13.18 (-24.49 to -1.88)-11.39 (-23.02 to 0.24)
Symptom scale/item: Nutritional supplements0.351 (-7.19 to 7.89)-4.37 (-12.23 to 3.49)
Symptom scale/item: Feeding tube-6.36 (-9.58 to -3.15)-0.11 (-3.30 to 3.08)
Symptom scale/item: Weight loss-17.72 (-27.23 to -8.21)-9.47 (-19.16 to 0.22)
Symptom scale/item: Weight gain-3.03 (-10.08 to 4.02)5.16 (-1.96 to 12.27)
SecondarySummary of PFS and OS for P16 Negative (%Positive Tumor Cells < 70%)

A central test was defined as the tumor tissue-based p16 IHC test performed at a central laboratory (Ventana). The analysis of concordance between HPV status as assessed by local or central laboratory included the number and percentage of participants with p16 detected or not detected at the central laboratory, given that all local testing must have been negative for HPV in order for the patient to be eligible for the study. Initial analysis of the p16 status was based on the conventional cutoff of 70% p16-positive tumor cells to call out cases that might be considered HPV-positive. P16 expression was scored as positive if strong and diffuse nuclear and cytoplasmic staining was present in at least 70% of the tumor cells.

Time frame:
Screening
Reported as:
Median · months
Summary of PFS and OS for P16 Negative (%Positive Tumor Cells < 70%)
monthsPalbociclib + CetuximabPlacebo + Cetuximab
PFS3.7 (3.2 to 5.6)5.0 (3.3 to 7.2)
OS9.9 (7.1 to 13.9)8.0 (7.0 to 14.7)
SecondarySummary of PFS and OS Based on Investigator Assessment by Rb Expression >= 1%

Rb expression in the palbociclib and cetuximab treatment group, the relationship of the biomarker (individually) with PFS and OS were explored using graphical methods such as box plots, at baseline. The tumors of participants were Rb-positive, which was defined by Rb IHC with\>=1% positive tumor cells.

Time frame:
Screening
Reported as:
Median · months
Summary of PFS and OS Based on Investigator Assessment by Rb Expression >= 1%
monthsPalbociclib + CetuximabPlacebo + Cetuximab
PFS3.9 (3.5 to 6.2)4.6 (2.6 to 5.6)
OS10.5 (7.1 to 15.6)7.8 (6.9 to 11.8)
SecondaryTrough Plasma Concentration (Ctrough) and Within-participant Mean Steady-state Pre-dose Concentration (WPM-Ctrough) at Steady State for Palbociblib

Ctrough is steady-state pre-dose concentration, which was observed directly from data. WPM-Ctrough is within-participant mean steady-state pre-dose concentration. For palbociclib, a steady-state trough was to be defined as a pre-dose plasma concentration following at least 7 consecutive days of 125 mg daily dose without dosing interruption and the time window for the PK collection was to be between 24 hr +/- 2 hr and 24 min post-dose the day prior to PK collection and no more than 1 hr post-dose on the day of PK collection.

Time frame:
Pre-dose of Day 15 in Cycle 1 and Cycle 2
Reported as:
Mean · nanograms per milliliter (ng/ml)
Trough Plasma Concentration (Ctrough) and Within-participant Mean Steady-state Pre-dose Concentration (WPM-Ctrough) at Steady State for Palbociblib
nanograms per milliliter (ng/ml)Palbociclib + Cetuximab
Ctrough Cycle 1 Day 1569.8 ± 28.208
Ctrough Cycle 2 Day 1567.8 ± 28.905
WPM-Ctrough71.6 ± 30.183
SecondaryCtrough and Cendinf, WPM-Ctrough and WPM-Cendinf at Steady State for Serum Cetuximab

Ctrough is steady-state pre-dose concentration. Cendinf is steady-state end-of-infusion concentration. Ctrough and Cendinf were observed directly from data. WPM-Ctrough and WPM-Cendinf are within-participant mean steady-state pre-dose concentration and end-of-infusion concentration. Acceptance criteria for a steady-state Cendinf was defined as a PK sample that was 1) collected after at least 3 consecutive weeks of cetuximab IV infusions without interruption or prior dose reduction and 2) was collected at the end of cetuximab infusion time +/- 10% of the actual duration of the cetuximab infusion.

Time frame:
Pre-dose and end-of infusion of Day 15 in Cycle 1 and Cycle 2
Reported as:
Geometric mean · ng/ml
Ctrough and Cendinf, WPM-Ctrough and WPM-Cendinf at Steady State for Serum Cetuximab
ng/mlPalbociclib + CetuximabPlacebo + Cetuximab
Ctrough Cycle 1 Day 1539706.4 ± 9242914.1 ± 62
Ctrough Cycle 2 Day 1551005.3 ± 7452995.7 ± 71
WPM-Ctrough45605.9 ± 8346796.5 ± 63
Cendinf Cycle 1 Day 15145748.3 ± 43137185.5 ± 61
Cendinf Cycle 2 Day 15149155.7 ± 38153310.1 ± 39
WPM-Cendinf149119.2 ± 36148063.3 ± 39

Adverse events

Collected over From the first dose through and including 28 calendar days after the last administration of the study treatment (up to 6.9 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Palbociclib + Cetuximab52/64 (81.3%)25/64 (39.1%)55/64 (85.9%)
Placebo + Cetuximab43/60 (71.7%)19/60 (31.7%)53/60 (88.3%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventPalbociclib + CetuximabPlacebo + Cetuximab
Disease progressionGeneral disorders7/646/60
PneumoniaInfections and infestations4/640/60
SepsisInfections and infestations0/642/60
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/642/60
Febrile neutropeniaBlood and lymphatic system disorders2/640/60
AnaemiaBlood and lymphatic system disorders0/641/60
Duodenal ulcer haemorrhageGastrointestinal disorders0/641/60
DysphagiaGastrointestinal disorders0/641/60
NauseaGastrointestinal disorders0/641/60
Anaphylactic reactionImmune system disorders0/641/60
Most frequent other events
Showing 10 of 42
Most frequent other events
EventPalbociclib + CetuximabPlacebo + Cetuximab
RashSkin and subcutaneous tissue disorders27/6421/60
AnaemiaBlood and lymphatic system disorders23/648/60
NeutropeniaBlood and lymphatic system disorders19/640/60
Dermatitis acneiformSkin and subcutaneous tissue disorders14/6413/60
LeukopeniaBlood and lymphatic system disorders13/640/60
Decreased appetiteMetabolism and nutrition disorders12/6410/60
White blood cell count decreasedInvestigations11/640/60
HypomagnesaemiaMetabolism and nutrition disorders11/648/60
Platelet count decreasedInvestigations10/640/60
DiarrhoeaGastrointestinal disorders9/645/60

Baseline characteristics

Baseline analysis population included all participants who were randomized.

Age, Continuous
Age, Continuous(years)Palbociclib + CetuximabPlacebo + CetuximabTotal
Mean58.3 ± 10.260.9 ± 10.159.5 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Palbociclib + CetuximabPlacebo + CetuximabTotal
Female8412
Male5756113
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Palbociclib + CetuximabPlacebo + CetuximabTotal
White474693
Black112
Asian151328
Other202
08

Study locations

71 sites
  • UC San Diego Medical Center - La Jolla (Thornton Hospital)
    La Jolla, California 92037, United States
  • UC San Diego Moores Cancer Center
    La Jolla, California 92093, United States
  • UC San Diego Medical Center- Hillcrest
    San Diego, California 92103, United States
  • University Medical Center, lnc.:DBA University of Louisville Hospital
    Louisville, Kentucky 40202, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Siteman Cancer Center - West County
    Creve Coeur, Missouri 63141, United States
  • Barnes-Jewish Hospital
    Saint Louis, Missouri 63110, United States
  • Washington University School of Medicine, Siteman Cancer Center
    Saint Louis, Missouri 63110, United States
  • Siteman Cancer Center - South County
    Saint Louis, Missouri 63129, United States
  • Siteman Cancer Center
    Saint Peters, Missouri 63376, United States
  • University of Cincinnati Investigational Pharmacy
    Cincinnati, Ohio 45219, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
  • UC Health Physicians Office South
    West Chester, Ohio 45069, United States
  • Henry Joyce Cancer Clinic
    Nashville, Tennessee 37232, United States
  • Fakultni nemocnice Olomouc
    Olomouc, 775 20, Czechia
  • Fakultni nemocnice Olomouc, Lekarna
    Olomouc, 77520, Czechia
  • Nemocnice Na Bulovce, Centralni laboratore Pavilon c. 8
    Praha 8, 180 81, Czechia
  • Nemocnice Na Bulovce, Lekarna, Oddeleni Centralni pripravy
    Praha 8, 180 81, Czechia
  • Nemocnice Na Bulovce, Ustav radiacni onkologie
    Praha 8, 180 81, Czechia
  • Debreceni Egyetem klinikai Koezpont Onkologiai Intezet
    Debrecen, 4032, Hungary
  • Neuro CT Kft
    Pecs, 7623, Hungary
  • Pecsi Tudomanyegyetem, Klinikai Kozpont, Laboratoriumi
    Pecs, 7624, Hungary
  • Pecsi Tudomanyegyetem, Klinikai Kozpont,
    Pecs, 7624, Hungary
  • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet,Onkologiai Kozpont
    Szolnok, 5000, Hungary
  • Istituto Nazionale Tumori Napoli
    Napoli, 80131, Italy
  • Aichi cancer center Central hospital
    Nagoya, Aichi 464-8681, Japan
  • National Cancer Center Hospital East
    Kashiwa, Chiba 277-8577, Japan
  • Hokkaido University Hospital/Otolaryngology
    Sapporo, Hokkaido 060-8648, Japan
  • Shizuoka Cancer Center
    Sunto-gun, Shizuoka 411-8777, Japan
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Instituto Nacional de Cancerologia
    Mexico, Distrito Federal 14080, Mexico
  • Hospital Universitario Dr. Jose Eleuterio Gonzalez
    Monterrey, Nuevo LEON 64460, Mexico
  • Cirugia y Ginecobstetricia de Oaxaca S.A de C.V Hospital Reforma
    Oaxaca, Oaxaca DE Juarez 68000, Mexico
  • Diaz San Juan Noe, Imagenologia Siglo XXI San Felipe
    Oaxaca, Oaxaca DE Juarez 68020, Mexico
  • Daniel Javier Mendez Lopez Imagen y Diagnostico Medico IDM
    Oaxaca, Oaxaca DE Juarez 68120, Mexico
  • Oaxaca Site Management Organization S C
    Oaxaca, 68000, Mexico
  • Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im. ks. B. Markiewicza
    Brzozow, 36200, Poland
  • Uniwersyteckie Centrum Kliniczne Klinika Onkologii i Radioterapii
    Gdansk, 80-211, Poland
  • Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi Oddzial Chemioterapii
    Lodz, 93-513, Poland
  • SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie Oddzial Kliniczny Onkologii
    Olsztyn, 10-228, Poland
  • SC Medisprof SRL
    Cluj-Napoca, Cluj 400058, Romania
  • Centrul de Oncologie Sf. Nectarie SRL
    Craiova, Dolj 200347, Romania
  • SC Oncolab SRL
    Craiova, Dolj 200385, Romania
  • S.C. ONCOCENTER Oncologie Clinica S.R.L.
    Timisoara, Timis 300166, Romania
  • Spitalul Clinic Judetean de Urgenta Sibiu, Clinica Oncologie Medicala
    Sibiu, 550245, Romania
  • State Budgetary Healthcare Institution of Arkhangelsk Region
    Arkhangelsk, Arkhangelsk Region 163045, Russian Federation
  • State Budgetary Healthcare Institution "Oncology Center #2" of the Ministry of
    Sochi, Krasnodar Region 354057, Russian Federation
  • State Autonomous Healthcare Institution Republican Clinical Oncology Dispensary of the Ministry
    Kazan, Tatarstan Republic 420029, Russian Federation
  • FSBI "National Medical Scientific Centre of Oncology n.a.N.N.Petrov" of the MOH of Russia
    Saint-Petersburg, 197758, Russian Federation
  • Institute for Oncology and Radiology of Serbia
    Belgrade, 11000, Serbia
  • Military Medical Academy
    Belgrade, 11000, Serbia
  • Narodny onkologicky ustav
    Bratislava, 83310, Slovakia
  • POKO Poprad, s.r.o.
    Poprad, 05801, Slovakia
  • Servicio de Oncologia
    Pamplona, Navarra 31008, Spain
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Taichung Veterans General Hospital
    Taichung City, 407, Taiwan
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 70154, Taiwan
  • National Cheng Kung University Hospital Department of Pathology
    Tainan, 704, Taiwan
  • Tri-Service General Hospital
    Taipei, 114, Taiwan
  • Communal Institution of Kherson Regional Council Kherson Regional Oncological Dispensary
    Antonivka, Kherson Region 73000, Ukraine
  • Communal Institution "Chernivtsi Regional clinical oncology dispensary",
    Chernivtsy, 58013, Ukraine
  • SI Dnipropetrovsk Medical Academy of MoH of Ukraine, Chair of Oncology and Medical Radiology
    Dnipropetrovsk, 49044, Ukraine
  • CI Dnipropetrovsk City Multifunctional Clinical Hospital #4 of Dnipropetrovsk Regional Council
    Dnipropetrovsk, 49102, Ukraine
  • Regional Clinical Hospital, Department of microsurgery of otolaryngology organs
    Ivano-Frankivsk, 76018, Ukraine
  • Communal Institution "Krivorizhskiy Oncology Dispensary" of Dnipropetrovsk Regional Council,
    Kriviy Rig, 50048, Ukraine
  • Clinic of SI "Institute of Otolaryngology n.a. Prof. O.S. Kolomyichenka of NAMSU"
    Kyiv, 03057, Ukraine
  • Podilskiy Regional Center of Oncology, Chemotherapy Department
    Vinnytsia, 21029, Ukraine
09

References and documents

Publications

  • Adkins DR, Lin JC, Sacco A, Ley J, Oppelt P, Vanchenko V, Komashko N, Yen CJ, Wise-Draper T, Lopez-Picazo Gonzalez J, Radulovic S, Shen Q, Thurm H, Martini JF, Hoffman J, Huang X, Melichar B, Tahara M. Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naive, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial. Oral Oncol. 2021 Apr;115:105192. doi: 10.1016/j.oraloncology.2021.105192. Epub 2021 Feb 8. PubMed 33571736 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Jul 2018, 34 months.

Results were first posted in Sep 2019, 1 year 2 months after primary completion.

Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 34 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2015
First posted
Jul 15, 2015
StartActual
Sep 10, 2015
Primary completionActual
Jul 19, 2018
CompletionActual
Sep 7, 2022
Results first posted
Sep 20, 2019
Last update
Sep 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02499120
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 15, 2015
Start date
Sep 10, 2015
Primary completion
Jul 19, 2018
Completion
Sep 7, 2022
Results posted
Sep 20, 2019
Last update
Sep 8, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palbociclib

Start the discussion